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INTRODUCTION
Thymoma is an uncommon neoplasm derived
from epithelial cells of the thymus. It is well known
for several interesting features : association with my-
asthenia gravis (MG) or other autoimmune disease,
histologic variability, and heterogeneity of malig-
nant behavior (1, 2). Surgery remains the mainstay
of treatment, and radiation and chemotherapy also
have been applied widely as adjuvant and palliative
procedures (3-5) ; however, the optimal treatment
for invasive thymoma has long been debated. Re-
cently, new concepts regarding the clinical approach
to thymoma have emerged as a result of a more
evidence-based approach (6, 7). This article reviews
the therapeutic strategy for thymoma.
HISTOLOGICAL CLASSIFICATION
The histologic classification of thymoma has re-
mained a subject of controversy for many years (8).
In 1976, Rosai and Levine (1) proposed that thy-
moma is restricted to neoplasms of thymic epithe-
lial cells and is divided into benign encapsulated
(noninvasive) and malignant invasive thymoma. Two
years later, they divided malignant thymoma into
invasive but cytologically bland thymoma (malignant
thymoma, category I) and cytologically malignant
epithelial tumors, which correspond to thymic car-
cinoma (malignant thymoma, category II) (9). In
1989, Muller-Hermelink and associates (10) divided
thymic epithelial tumors into medullary, mixed me-
dullary and cortical, predominantly cortical, corti-
cal thymoma, well-differentiated thymic carcinoma
and high-grade carcinoma. This classification was
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reported to be useful for predicting the outcomes of
patients with these tumors (11, 12).
In 1999, the World Health Organization (WHO)
Consensus Committee published a histologic typing
system of tumors of the thymus (13). Thymomas
are stratified into six entities (types A, AB, B1, B2,
B3, and C) on the basis of the morphology of epi-
thelial cells and the lymphocyte-to epithelial cell
ratio (Table 1). The WHO Consensus Committee
(2004) recently proposed that thymic epithelial tu-
mors consist of thymoma (type A, AB, B1, B2 and
B3) and thymic carcinoma, including neuroendo-
crine epithelial tumors of the thymus (well-differ-
entiated neuroendocrine carcinoma ; typical carci-
noid and atypical carcinoid, poorly differentiated
neuroendocrine carcinoma ; large cell neuroendo-
crine carcinoma and small cell carcinoma) (14).
Recently many reports have discussed the impact
of the WHO system on clinical management deci-
sions (whether the classification is reproducible,
whether it defines clinically distinct patient groups,
whether it has independent prognostic value) (15-
25). The WHO classification system does appear to
be an advance in our understanding of thymoma.
Detterbeck summarized that the WHO classification
is reasonably reproducible, and general trends to-
ward different clinical characteristics of patients of a
particular subtype are suggested. In general, the
WHO classification has independent prognostic
value in addition to stage ; however, the value of his-
tologic classification is primarily in distinguishing
thymic carcinoma and, less clearly perhaps, type B3
from other types of thymoma (26).
CLINICAL STAGE
The clinical staging system for thymoma was first
introduced by Bergh and associates in 1978 (27),
later modified by Wilkins and Castleman (28),
and confirmed by Masaoka and associates in 1981
(Table 2) (29). A TNM staging system has been
proposed that closely parallels the Masaoka sys-
tem (Table 3) (30). In France, multiple centers
have adopted the Groupe d’Etudes des Tumeurs
Thymiques (GETT) staging system (Table 4), as
described by the French Study Group on Thymic
Tumours (31). In this system, the predominant fea-
ture is the extent of surgical resection. The clinical
staging of patients should be determined before
treatment to select the optimal approach.
The Masaoka classification is now the most widely
accepted and is an excellent predictor of the prog-
nosis of thymoma (2, 3, 6, 7, 32) ; however, several
Table 2. Masaoka Staging System
I Macroscopically encapsulated tumor, with no microscopic capsular invasion
II Macroscopic invasion into surrounding fatty tissue or mediastinal pleura
Microscopic invasion into the capsule
III Macroscopic invasion into neighboring organs
IV a Pleural or pericardial metastases
b Lymphogenous or hematogenous metastasis
Table 1. World Health Organization Histologic Classification
A A tumor composed of a population of neoplastic thymic epithelial cells having a spindle/oval shape, lacking nuclear atypia, and
accompanied by few or no non-neoplastic lymphocytes.
AB A tumor in which foci having the features of type A thymoma are admixed with foci rich in lymphocytes.
B1 A tumor that resembles the normal functional thymus in that it combines large expanses practically indistinguishable from
normal thymic cortex with areas resembling thymic medulla.
B2 A tumor in which the neoplastic epithelial component appears as scattered plump cells with vesicular nuclei and distinct nucle-
oli among a heavy population of lymphocytes. Perivascular spaces are common and sometimes very prominent. A perivascular
arrangement of tumor cells resulting in a palisading effect may be seen.
B3 A type of thymoma predominantly composed of epithelial cells having a round or polygonal shape and exhibiting no or mild atypia.
They are admixed with a minor component of lymphocytes, resulting in sheetlike growth of neoplastic epithelial cells.
C A thymic tumor exhibiting clear-cut cytologic stypia and a set of cytoarchitectural features no longer specific to the thymus,
but rather analogous to those seen in carcinomas of other organs. Type C thymomas lack immature lymphocytes. The lympho-
cytes present are mature and usually admixed with plasma cells.
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articles have pointed out problems and have sug-
gested that an update of the system is desirable (33,
34). 1) The classification system does not provide
appreciable prognostic separation between stages
I and II (2, 35, 36). 2) Some definitions are not clini-
cally applicable because surgical or pathological as-
sessment is required. In particular, the definition of
stage II is unclear. Some pathologists propose that
microscopic invasion into the capsule in stage II
should be replaced by microscopic transcapsular
invasion (2, 8). The most recent World Health Or-
ganization classification of thymic epithelial tumors
in 2004 defined T2 thymoma as “tumor invades peri-
capsular connective tissue” (14). 3) As stage III thy-
moma is highly heterogenous in terms of the in-
volved organs, the classification should divide the
subgroups according to prognosis. Okumura and
associates (37) reported that involvement of the
great vessels is an independent prognostic factor in
patients with stage III thymoma. 4) The system is
not well suited to staging thymic carcinomas (38,
39). The TNM system classification of thymic epi-
thelial tumors has not been established. Yamakawa
and Masaoka (30) presented a tentative TNM sys-
tem classification of thymoma in 1991, which some
reports subsequently supported. In Masaoka’s sys-
tem, the presence of local invasion (T factor) is
strongly emphasized in comparison with lymphoge-
nous and hematogenous metastasis (N and M fac-
tors) because of the rarity of lymphogenous and
hematogenous metastasis in thymoma. However,
it is necessary to determine how N or M factors in-
fluence prognosis to establish a TNM system clas-
sification of thymic epithelial tumors, including thy-
mic cancer and carcinoid. The WHO histologic clas-
sification of 2004 (14), which can distinguish thymic
carcinoma and carcinoid from thymoma, has been
widely adopted, and large-scale clinicopathologic
studies of thymic carcinoma and carcinoid may pro-
vide sufficient prognostic information to include N
or M factors in a TNM system of thymic epithelial
tumor.
Table 3. TNM Classification of Thymic Epithelial Tumors
T factor
T1 : Macroscopically completely encapsulated and microscopically no capsular invasion
T2 : Macroscopically showing adhesion or invasion into surrounding fatty tissue or mediastinal pleura, or microscopic invasion
into capsule
T3 : Invasion into neighboring organs, such as pericardium, great vessels, and lung
T4 : Pleural or pericardial dissemination
N factor
N0 : No lymph node metastasis
N1 : Metastasis to anterior mediastinal lymph nodes
N2 : Metastasis to intrathoracic lymph nodes except anterior mediastinal lymph nodes
N3 : Metastasis to extrathoracic lymph nodes
M factor
M0 : No hematogenous metastasis
M1 : Hematogenous metastasis
Table 4. GETT Staging System of Thymomas
Stage I
Ia Encapsulated tumor, totally resected
Ib Macroscopically encapsulated tumor, totally resected, but the surgeon suspects mediastinal adhesion and potential capsular
invasion
Stage II
Invasive tumor, totally resected
Stage III
IIIa Invasive tumor, subtotally resected
IIIb Invasive tumor, biopsy
Stage IV
IVa Supraclavicular metastasis or distant pleural implant
IVb Distant metastases
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THERAPY
Surgery remains the mainstay of treatment for
thymic epithelial tumors, and radiation and chemo-
therapy also have been applied widely as adjuvant
and palliative procedures (2, 3, 6, 7). The treatment
of thymoma depends upon its clinical stage. Kondo
and Monden presented the therapeutic modality of
1,093 patients with thymoma in Japan (32). Most
patients with stage I thymoma underwent only sur-
gery. About half of the patients with stage II thy-
moma and three-fourths of the patients with stage
III thymoma underwent surgery with adjuvant ther-
apy. Most of the adjuvant therapy in stages I, II,
and III thymomas consisted of radiotherapy. Sev-
enty percent of patients with stage IV thymoma un-
derwent surgery with adjuvant therapy. In more than
half, adjuvant therapy included chemotherapy.
1) SURGERY
Surgical resection is the mainstay of thymoma
treatment, because most of these tumors are local-
ized (7, 30). The reported operative mortality is
an average of 2.5% (0.7%-4.9%) (6, 7). Surgery for
thymic epithelial tumors was classified into three
groups : total resection (no tumor remained mac-
roscopically), subtotal resection (almost all of the
tumor was resected macroscopically), and inoper-
able (including partial resection, exploratory thora-
cotomy and simple biopsy) groups. The resectabil-
ity rates of stage I, II, III, and IV thymomas were
100%, 100%, 85%, and 42%, respectively (32). Det-
terbeck surmmarized from 8 series of more than 100
patients with thymoma that the average resectabil-
ity rates of stage I, II, III, and IV thymomas were
100%, 80% (43-100%), 47% (0-89%), and 26% (0-78%),
respectively. Several large studies (100 patients)
demonstrated that completeness of resection is an
independent prognostic factor using multivariate
analysis (7).
2) RADIOTHERAPY
A) Postoperative radiotherapy
Most authors do not recommend radiotherapy af-
ter totally resected stage I (noninvasive) thymoma
(3, 5) ; however, recommendations for the appropri-
ate use of adjuvant radiation therapy for stage II or
III thymoma are controversial. We reviewed 11 pa-
pers in which patients with stage II or III thymoma
both received and did not receive adjuvant radia-
tion therapy after complete resection, thus enabling
a comparison between the two groups (Table 5)
(40-49). Monden and associates reported that 8%
and 24% of patients with postoperative radiotherapy
and 29% and 40% of patients without postoperative
radiotherapy relapsed in stage II and III thymoma,
respectively (40). Another nine papers (12, 42-49)
were unable to demonstrate an advantage over ra-
diation therapy in terms of recurrence including lo-
cal, pleural dissemination and distant metastasis. In
patients with stage II thymoma, recurrence rates
ranged from 0% to 31% after radiation, and from 0%
to 29% without radiation. In patients with stage III
thymoma, recurrence rates ranged from 13% to 64%
after radiation, and from 13% to 52% without radia-
tion. These differences did not reach statistical sig-
nificance, except in a paper by Ruffini and associates
(45), who demonstrated a significant advantage to
not receiving adjuvant radiation (p=0.02). We do
not recommend adjuvant radiation therapy as a
means to prevent recurrence, including local, pleu-
ral dissemination and distant metastasis, for patients
with completely resected stage II and III thymoma.
Haniuda and associates reported that 19% of patients
with postoperative radiotherapy and 12% of patients
without postoperative radiotherapy had pleural dis-
semination in stage II and III thymoma, and rec-
ommended that mediastinal irradiation may have
been effective in preventing local recurrence, al-
though it did not control pleural dissemination (44).
On the other hand, two reports demonstrated an
advantage to radiation therapy in terms of mediasti-
nal recurrence. Curran, et al. reported that no pa-
tient with postoperative radiotherapy and 33% and
67% of patients without postoperative radiotherapy
relapsed in stage II and III thymoma, respectively
(41). Haniuda, et al. reported that 3.6% of patients
with postoperative radiotherapy and 17.2% of pa-
tients without postoperative radiotherapy relapsed
in stage II and III thymoma (44). Another five pa-
pers (12, 32, 47-49) were unable to demonstrate an
advantage to radiation therapy in terms of local
recurrence. Although the utility of postoperative
mediastinal radiotherapy in preventing local recur-
rence in patients with completely resected stage II
and III thymoma is controversial, the frequency of
cases with only local recurrence is low.
Moreover, there are some late complications of
radiation therapy to the chest (hematopoietic malig-
nancies, esophageal malignancies, dysmotility and
strictures, or radiation pneumonitis and chronic pul-
monary fibrosis) and the heart (cardiac valve fibro-
sis, pericardial effusions, or accelerated coronary
artery disease) (46, 49).
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We recommend that patients with completely re-
sected stage II and III thymoma should be followed
with long-term serial physical and radiological ex-
amination, as this disease has an indolent natural
history. If these patients develop recurrence, they
should be treated by radiotherapy or surgery.
B) Radiotherapy for unresectable or locally advanced
disease
Thymomas are moderately radiosensitive. Radi-
cal postoperative radiotherapy may control resid-
ual disease and provide long-term, disease-free sur-
vival in a subset of patients after incomplete resec-
tion. Loehrer summarized selected clinical experi-
ences for which approximate 5 -year data are avail-
able and noted that approximately two thirds of pa-
tients with locally advanced disease were locally con-
trolled, with 5 -year survival rates of approximately
40% to 50% (6, 50 -55).
Stage III and stage IV thymomas with significant
macroscopic infiltration to neighboring structures
are rarely completely resectable. In incompletely
resected invasive thymoma, whether tumor debulk-
ing following radiotherapy influences prognosis
and local control is unclear. Mornex and associates
reviewed the cases of 90 patients (biopsy only in 55
patients and partial resection in 31 patients) with
incompletely resected invasive thymoma. There was
a great impact of the extent of surgery on survival :
5 - and 10 -year survival rates were 64% and 43%, re-
spectively, after partial resection, compared to 39%
and 31% after biopsy, p0.02). There is a significant
Table 5. Postoperative radiotherapy for patients with completely resected stage II and III thymoma
number of patients recurrence rate* mediastinal recurrence rate
Author period total cases stage with radiation without radiation with radiation without radiation with radiation without radiation
Monden
et al. 40) 127 II 25 7 8.0% 29.0% - -
III 34 10 29.0% 40.0% - -
Curran
et al. 41)$ 1960-1985 117 II 1 18 - - 0% 33.0% 6
III 4 3 - - 0% 66.7% 2
Quintanilla-
Martinez
et al. 12)#
1970-1990 116 II 7 24 23.0% 8.0% 14.3% 1 0%
III 15 8 13.0% 13.0% 0% 0%
Blumberg
et al. 42) 1949-1993 118 II 9 17 similar rate - -
III 17 5 48.0% 52.0% - -
Regnard
et al. 43) 1955-1993 307 II and III 90 24 30.0% 45.0% (10-year) - -
41.0% 45.0% (15-year) - -
Haniuda
et al. 44) 1973-1992 89 II 16 21 18.8% 23.8% 3.6% 1 17.2% 5
III 12 8 25.0% 25.0%
Ruffini
et al. 45) & 1974-1993 310 II 13 45 31.0% 4.0% - -
III 14 36 64% 16% - -
Mangi
et al. 47)46)# 1972-1999 155 II 14 35 0% 2.9% 0% 0%
III 38 7 32% 29% 0% 0%
Kondo and
Monden 32) 1990-1994 1093 II 86 122 4.7% 4.1% 0.0% 1.6% 2
III 78 31 23.0% 26.0% 5.1% 4 3.1% 1
Singhal
et al. 48)$ 1992-2002 167 II 20 20 5.0% 0.0% 0.0% 0.0%
Rena
et al. 49)& 1988-2000 197 II 26 32 11.5% 6.3% 3.8% 1 3.1% 1
* including preural dissemination and distant metastasis
#, $, & same institute
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relationship between the extent of surgery and lo-
cal failure (16% of relapse after partial resection vs.
45% after biopsy, p  0.05) (56). Pollack and asso-
ciates also reported that the disease-free survival
rate by the extent of surgery was 60% for subtotal
resection and 20% for biopsy only (54). Other stud-
ies have described better clinical outcomes with tu-
mor debulking comparing with biopsy only in pa-
tients with incompletely resectable thymomas (29,
51, 52, 54).
On the other hand, Ciernik and associates re-
viewed the cases of 31 patients (biopsy only in 16
patients and subtotal in 15 patients) with incom-
pletely resected stage III and IV thymomas follow-
ing postoperative irradiation. They demonstrated
that both groups yielded similar results in respect
to survival and local tumor control. Local recurrence
or local tumor progression was not influenced by
the amount of surgery (tumor debulking vs biopsy)
or by the stage of the thymoma (56). Other studies
have not shown any consistent significant benefit of
postoperative radiotherapy after incomplete or sub-
total resection (57-59).
3) CHEMOTHERAPY
Hejina, et al. summarized the efficacy of single
agent cisplatin for thymoma and that 3 (14.3%)
and 6 (28.6%) patients achieved complete remis-
sion (CR), resulting in an overall response rate
of 43% (5). Park and associates reported a high re-
sponse rate to cisplatin with or without predoni-
sone (6 CR (35%), 5 partial remission (PR) (29%),
for an overall response rate of 64%). Patients with
response to therapy had a significantly longer me-
dian survival time than nonresponders (67 months
vs 17 months) (61). Hejina and associates also sum-
marized 2 CR (15%) and 9 PR (69%) with the appli-
cation of steroid therapy as a single treatment mo-
dality (5).
The Southeastern Cancer Study Group initiated
one of the first prospective trials evaluating combi-
nation chemotherapy in 1983 (62, 63). This trial was
designed to identify the activity of cisplatin, dox-
orubicin, and cyclophosphamide (PAC) in patients
with unresectable or advanced thymoma. In patients
with advanced disease, patients received up to six
cycles of PAC chemotherapy. A 50% response rate
(three complete and 12 partial responses) was noted
in 30 assessable patients treated with PAC chemo-
therapy. The median survival time was 38 months
and the 5 -year survival rate was 32% (62). In pa-
tients with limited disease (defined as encompass-
able in a single radiotherapy portal), the trial design
was to administer two to four cycles of PAC followed
by radiotherapy. PAC produced a 70% response rate
before radiation therapy in 23 assessable patients,
with an approximate 50% 5 -year survival rate (63).
Forniasiero, et al. , who treated 37 patients with stage
III and IV invasive thymomas using combination
chemotherapy with doxorubicin, cisplatin, vincris-
tine, and cyclophosphamide (ADOC) at monthly in-
tervals. A median of five courses of the described
ADOC regimen (3 -7 courses) was administered. A
47% complete and 90% overall response rate was ob-
served. The median survival time (MST) was only
15 months. The MST of 16 patients with complete
remission was 27 months, and 18 patients with a
partial response was 9.5 months (64).
Giaccone, et al. reported the results of a trial
conducted by the European Organization for Re-
search and Treatment of Cancer using cisplatin and
etoposide. Among 16 patients with recurrent or me-
tastatic thymoma, 33% complete and 60% overall re-
sponse rate was observed, with a median progres-
sion-free survival time of 2.2 years and a median
survival time of 4.3 years (65). An intergroup trial
coordinated by the Eastern Cooperative Oncology
Group evaluated ifosfamide, etoposide, and cis-
platin in 28 patients with recurrent and metastatic
thymoma, including 8 thymic carcinoma. Among
28 evaluable patients, there were no complete re-
sponses and 9 partial responses (32%). The me-
dian duration of response was 11.9 months, and
median overall survival was 31.6 months. Among
20 patients with thymoma, 0% complete and 35%
overall response rate was observed. The 1-year and
2-year survival estimates for thymoma patients
were 95% and 79%, respectively (66).
We reviewed 9 papers in which patients with stage
III or IV thymoma received multimodality treatment
(preoperative chemotherapy, surgery, and postop-
erative chemotherapy or radiotherapy) (Table 6)
(67-75). The results of induction chemotherapy in
these studies demonstrated that thymomas are sen-
sitive to chemotherapy. The regimen in most stud-
ies was cisplatin/doxorubicin-based combination
chemotherapy (ADOC ; 3 studies, cisplatin + epiru-
bicin + etoposide : 3 studies, PAC + steroid ; cisplatin
+ doxorubicin + cyclophosphamide + steroid : 2 stud-
ies, PAC : 1 study, cisplatin + etoposide : 1 study,
and doxorubicin + cisplatin + steroid : 1 study), and
the regimen cycles were 3 - 4 times. Considerable
chemosensitivity was observed in these studies with
an objective response of 67%-100%, a complete re-
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sponse of 7-57%, and a pathologic complete response
of 7-31%, although the response rate was slight low
in studies including thymic carcinoma (67% -72%).
In summary, thymomas are sensitive to chemo-
therapy, with an objective response seen in an av-
erage of two thirds of patients (67% -100%), and com-
Table 6. Multimodality Therapy for patients with advanced (stage III and IV) thymoma
Author number of Pts# stage Regimens of preoperative chemotherapy cycle CR rate$ pCR& response rate
Macchiarini
et al. 67) 7* III cisplatin, epirubicin, etoposide 3 57% 29% 100%
Berruti A
et al. 68) 6 III and IVA ADOC 4 - - 83%
Rea
et al. 69) 16 III and IVA ADOC 3 or 4 43% 31% 100%
Shin
et al. 70) 13 III and IVA
cisplatin, doxorubicin, cyclophosphamide, predni-
sone 25% 17% 92%
Venuta
et al. 71) 15* III cisplatin, epirubicin, etoposide (early 8 patients) 13% 7% 67%
cisplatin, adriblastin, cyclophosphamide
Bretti
et al. 72) 25* III and IVA ADOC (18 cases) 4 8% 8% 72%
cisplatin, etoposide (7 cases)
Kim
et al. 73) 22 III and IV
cisplatin, doxorubicin, cyclophosphamide, predni-
sone 3 14% 9% 77%
Lucchi
et al. 74) 30 III and IVA cisplatin, epidoxorubicin, etoposide 3 7% - 73%
Yokoi
et al. 75) 14 III and IVA cisplatin, doxorubicin, methylpredonisolone 4 7% - 93%
# Pts = patients
$ CR rate =complete remission rate
& pCR = pathological complete remission
!DFS = disease-free survival
* including thymic carcinoma
ADOC ; doxorubicin, cisplatin, vincristine, cyclophosphamide
surgery complete resection rate radiotherapy postoperative chemotherapy cycle DFS! overall survival
+ 57% 45Gy-com - - - -
60Gy-incom
+ 83% - - - -
+ 69% 11 cases-Rad+ ADOC (5 cases) 3 - 70 (3y)
+ 92% 50 Gy-com cisplatin, doxorubicin, cyclophosphamide,prednisone - 73% (7 y) 100% (7y)
60Gy-incom,<80%
+ 91% in only thymoma 40Gy-com cisplatin, epirubicin, etoposide (8 patients) 2 or 3 - -
50-60Gy-incom cisplatin, adriblastin, cyclophosphamide
+ 44% 45Gy-com - - - -
III-57%, IVA-27% 55Gy-incom
+ 76% 50Gy-com, cisplatin, doxorubicin, cyclophosphamide,prednisone 3 77% (5y) 95% (5y)
60Gy-incom, <80% 77% (7y) 79% (7y)
+ 77% 45Gy-com cisplatin, epidoxorubicin, etoposide - - 82% (10y)
60Gy-incom 8 cases III-86%
21 cases IVA-76%
+ 22% 50Gy - - - 81% (5y, 10y)
9 cases 8 cases III-100% (10y)
IVA-89% (10y)
The Journal of Medical Investigation Vol. 55 February 2008 23
plete response in one third (7% -57%). Cisplatin/dox-
orubicin-based combination chemotherapy seems
to produce the best overall response rate and sur-
vival.
4) MULTIMODALITY THERAPY
Macchiarini, et al. were among the first to evalu-
ate preoperative chemoradiotherapy in patients with
stage III thymoma (67). Seven patients received
three cycles of cisplatin, epirubicin, and etoposide
before surgery. Four patients, including 2 pathologi-
cal CR cases, experienced complete remission (ob-
jective response 70%) and the response rate was
100%. A similar disease trial was also developed in
8 studies (Table 6) (68 -75), most of which were con-
trolled prospective trials. The probability to achieve
complete resection after induction chemotherapy was
69 -92%, except in the worst 2 studies (22%-44%), al-
though differences in the resectability rate may re-
flect the willingness of surgeons to undertake more
extensive operations and the extent of invasiveness
before chemotherapy. Postoperative radiotherapy
was performed at doses of 40 -50 Gy for patients
with complete resection or 50 - 60 Gy for patients
with incomplete resection. In 5 studies, postopera-
tive chemotherapy was performed using the same
regimen as for preoperative chemotherapy. The 7-
year disease-free survival and overall survival was
73 -77% and 79 -100%, respectively.
In summary, these series suggest that resectabil-
ity and survival may be improved with multimodal-
ity treatment (preoperative chemotherapy, surgery,
and postoperative chemotherapy or/and radiother-
apy) in patients with stage III and IV thymomas.
There is a need for prospective, large intergroup-
driven trials to help identify the optimal multimo-
dality therapy for this disease.
CONCLUSION
Despite an indolent course and a cytologically
bland appearance, all thymic tumors can manifest
malignant behavior. The WHO classification is rea-
sonably reproducible, and can be divided into dif-
ferent clinical characteristics of thymic epithelial
tumor. It is necessary to perform a large intergroup-
driven study because of the rarity of thymic epi-
thelial tumor ; however, the value of histologic clas-
sification remains primarily in distinguishing thy-
mic carcinoma, and type B3 from other types of
thymoma. The Masaoka classification is the most
widely accepted and is an excellent predictor of the
prognosis of thymoma, although an update of this
system is desirable. Optimal treatment for thymoma
should be performed according to its clinical stage.
Surgery continues to be the mainstay of treatment,
and the ability to achieve complete resection ap-
pears to be the most important prognostic factor ;
therefore, every effort must be made at the time of
resection to achieve this. Thymomas also have a
high response rate to chemotherapy or radiother-
apy. Only surgical resection should be performed
for patients with stage I (non-invasive) thymoma.
The value of postoperative radiotherapy in com-
pletely resected stage II or III tumors is question-
able, but there is a benefit of postoperative radio-
therapy in patients who are incompletely resected.
Multimodality therapy involving preoperative che-
motherapy and postoperative radiotherapy or/and
chemotherapy appears to increase the rate of com-
plete resection and improve survival in advanced
(stage III and IV) thymomas.
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